U.S. Markets closed

Capricor Therapeutics, Inc. (CAPR)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.18-0.38 (-6.83%)
At close: 4:00PM EDT

5.18 0.00 (0.00%)
After hours: 4:05PM EDT

Sign in to post a message.
  • A
    Albrecht
    I think it's pretty safe to say, that folks who listened to CAPR's presentation this week liked what they heard and are now positioning themselves for when news hits. I think last time it peaked just a bit over $12 but I think we will easily surpass that at the next significant news event.
  • t
    twilight
    Possible partners as Linda mentioned yesterday that they are looking for partners
  • P
    Parimal
    Linda said yesterday that Exosomes preclinical trials are in it's last stage means data coming within couple weeks.. stay long and you will get good rewards...
  • T
    Toughman711
    Interesting post I just read from a couple other forums just now...seems as though some type of application was either filed or issued from the us patent office today
  • I
    Ian
    not selling below...well a large number :) long means more than a few months, holding this baby for a few years and lets see what happens
    Bullish
  • G
    Ghost
    People often refer to the FDA approval of Sarepta's drug Exondys 51 after the FDA advisory committee initially voted against approval, to gauge whether the FDA will grant accelerated approval to CAP-1002.

    https://www.raps.org/regulatory-focus™/news-articles/2016/9/sarepta-wins-controversial-fda-approval-for-first-dmd-drug

    "The agency’s approval went against the recommendation of its experts. The main clinical trial of the drug was small, involving only 12 boys with the disease known as Duchenne muscular dystrophy, and did not have an adequate control group of boys who had the disease but did not take the drug. A group of independent experts convened by the agency this spring said there was not enough evidence that it was effective." https://www.nytimes.com/2016/09/20/business/fda-approves-muscular-dystrophy-drug-that-patients-lobbied-for.html

    I agree that the evidence for CAP-1002's efficacy is much better than with Exondys 51 was when it was approved. But I do not know if the current internal FDA politics will work for or against us. There was a lot of controversy surrounding the Sarepta decision.

    https://www.statnews.com/2016/09/20/janet-woodcock-sarepta-fda/
    https://www.biospace.com/article/meet-the-powerful-woman-behind-the-scenes-of-sarepta-s-dmd-drug-approval-/
  • J
    Joseph S
    watched this 2x today https://wsw.com/webcast/hcw7/capr/1595926
    market cap below $100m is nuts, even below 200m is a head scratcher without any news.
    If you are an investor in $CAPR I urge you to DYOR, watch the video, learn about exosomes, study the pipeline and then and google stuff you don't understand if you didn't graduate med school. Then look and similar companies and see what they are valued at.
    Bullish
  • e
    elvis
    Linda you need to release great news right now before The Short and day traders bring the stock down again after a great day like yesterday 🙏🏻🙏🏻🙏🏻🙏🏻🙏🏻🙏🏻🙏🏻
  • n
    nutmeg
    popcorn be trippin...seriously though, these paid bashers are paid by the post...they are awarded more money for tags and engagement. don’t feed the monsters...
  • J
    Joe
    Linda should be updating the CAP-2003 study 2 years ago with Department Defence/Army for critical wounded soldiers. Grant ends this month and cash. Results have to be available this month.
    https://charts.stocktwits.com/production/original_242118245.png
  • A
    Asher
    News out today that mRNA vaccine companies have storage issues. Capricor's mRNA vaccine appears to not have these same issues because they are using durable exosome based vesicles to protect the fragile RNA sequences.

    https://www.marketwatch.com/story/moderna-and-pfizers-covid-19-vaccine-candidates-require-ultra-low-temperatures-raising-questions-about-storage-distribution-2020-08-27
    The COVID-19 vaccine candidates being developed by Moderna Inc. and BioNTech and Pfizer Inc. will require stringent standards for refrigeration, and that may...
    The COVID-19 vaccine candidates being developed by Moderna Inc. and BioNTech and Pfizer Inc. will require stringent standards for refrigeration, and that may...
    www.marketwatch.com
  • n
    nii
    This coming Tuesday this stock is going to the moon after that presentation. It's valuation is too low for what it has in it's pipeline.
    Bullish
  • J
    Joe
    Positions available - read thru linkdn they are adding 14 new positions to the 27 they have now most likely for commercializations, QC, approvals And PRs ect. Why else spend over 1 million in total salaries https://charts.stocktwits.com/production/original_242049559.png
  • G
    Greg
    We could have easily given back 50 percent of Thursday's gains today and we didn't. And as the other poster said the October options are pricing very bullish. So I'm now leaning a little more positive here. I'm not expecting a straight path upward however and I think there will be fairly significant resistance to work through the next time we pop above $6.
  • S
    SONIA
    Big international company buying them out. The announced closing will be 30 to 60 days from now. Price already starting to move up and very soon could spike big on announcement.
    https://seekingalpha.com/instablog/21922151-bioresearch-alert/5498768-reverse-merger-underway-protect-pharmaceutical-corp-and-novgorod-increase-prtt-sales-assets
    Reverse Merger Underway With Protect Pharmaceutical Corp And Novgorod Would Increase PRTT Sales, Assets, And Growth Dramatically - BioResearch Alert
    seekingalpha.com
  • G
    GoBlue
    Great volume and big move on no need. Very positive action. Should have follow thru even without PR
  • J
    Joe
    This is becoming very common in athletes - CAPR needs to come out to the organizations on what they do to support the heart and covid.
    https://sports.yahoo.com/ohio-state-study-4-of-26-athletes-who-tested-positive-for-covid-19-had-cmr-findings-suggestive-of-myocarditis-184819353.html
  • F
    FunAgain
    $INO conversation
    it's simple, INO profit taking... ACRX now up about 20%, on volume... might want to put ACRX on your watch list... my watch list includes $kodk $nvax $sava $capr
    Bullish
  • P
    Parimal
    looks like options expire today that's why it going down or follow whole market. NVAX also down more then 8% and lots of other covid-19 stocks down too. but oct. option market looking so bullish.